Trials / Unknown
UnknownNCT05147740
Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age
Switching to a Fixed Dose Combination of Biktarvy in Treatment Experienced People With HIV Who Are Currently Virologically Suppressed and at Least 65 Years of Age
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Tulika Singh, MD · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess patient reported treatment satisfaction and medication tolerability in virologically suppressed HIV-1 infected adults who are at least 65 years of age who switch to a bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | B/F/TAF | 50/200/25 mg fixed-dose combination administered orally once daily without regard to food. |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2021-12-07
- Last updated
- 2021-12-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05147740. Inclusion in this directory is not an endorsement.